Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR3 | P46089 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.41 |
| ▸ | PRNP | P04156 | 1/20 | 0.40 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.40 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.40 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.38 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 4/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.36 |
| ▸ | TUBB | P07437 | 1/20 | 0.36 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.36 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.36 |
| ▸ | TUBA4A | P68366 | 1/20 | 0.36 |
| ▸ | TUBB4B | P68371 | 1/20 | 0.36 |
| ▸ | TUBB3 | Q13509 | 1/20 | 0.36 |
| ▸ | TUBB2A | Q13885 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4093915 | 0.86 | GPR3 (0.44) | GPR3ALDH1A1PRNPRXFP1ALOX5 | |
| SCHEMBL4099685 | 0.81 | GPR3 (0.40) | GPR3ALDH1A1PRNPRXFP1ALOX5 | |
| SCHEMBL4099681 | 0.81 | GPR3 (0.40) | GPR3ALDH1A1PRNPRXFP1ALOX5 | |
| SCHEMBL22320228 | 0.81 | GPR3 (0.40) | GPR3ALDH1A1PRNPRXFP1ALOX5 | |
| SCHEMBL12896179 | 0.79 | GPR3 (0.46) | GPR3ALDH1A1ALOX5MAPTKMT2A | |
| SCHEMBL25604280 | 0.78 | GPR3 (0.44) | GPR3ALDH1A1ALOX5MAPTIDO1 | |
| SCHEMBL22789121 | 0.78 | GPR3 (0.44) | GPR3ALDH1A1ALOX5MAPTKMT2A | |
| SCHEMBL12767846 | 0.78 | ALOX5 (0.56) | GPR3ALDH1A1RXFP1ALOX5MAPT | |
| SCHEMBL13197121 | 0.76 | TRPA1 (0.34) | ROCK1IDO1CYP1A2 | |
| SCHEMBL14350411 | 0.76 | BCL2L1 (0.40) | ALDH1A1MAPTGAARAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230303581-A1 | ORALLY BIOAVAILABLE, BRAIN-PENETRANT COMPOUND WITH SELECTIVITY FOR THE CANNABINOID TYPE 2 RECEPTOR WITH POTENTIAL USE TOWARDS VISCERAL PAIN MANAGEMENT AND NEURODEGENERATIVE DISORDERS | UNIV MISSISSIPPI (US) | 2023-09-28 | — | — | US | disclosed |
| US-20230303581-A1 | ORALLY BIOAVAILABLE, BRAIN-PENETRANT COMPOUND WITH SELECTIVITY FOR THE CANNABINOID TYPE 2 RECEPTOR WITH POTENTIAL USE TOWARDS VISCERAL PAIN MANAGEMENT AND NEURODEGENERATIVE DISORDERS | UNIV MISSISSIPPI (US) | 2023-09-28 | — | — | US | disclosed |
| EP-3675847-B1 | SPIROCYCLE COMPOUNDS AND METHODS OF MAKING AND USING SAME | H LUNDBECK AS (DK) | 2023-07-12 | — | — | EP | disclosed |
| US-20230172047-A1 | ORGANIC LIGHT EMITTING DIODE AND ORGANIC LIGHT EMITTING DEVICE HAVING THEREOF | LG DISPLAY CO., LTD. (KR) | 2023-06-01 | — | — | US | disclosed |
| US-11236082-B2 | EZH2 inhibitors and uses thereof | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2022-02-01 | — | — | US | disclosed |
| US-20210163471-A1 | PROGRANULIN MODULATORS AND METHODS OF USING THE SAME | ARKUDA THERAPEUTICS | 2021-06-03 | — | — | US | disclosed |
| US-10702527-B2 | Combination therapy of transcription inhibitors and kinase inhibitors | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-07-07 | — | — | US | disclosed |
| US-20190192532-A1 | COMBINATION THERAPY OF BROMODOMAIN INHIBITORS AND CHECKPOINT BLOCKADE | PETER MACCALLUM CANCER INSTITUTE (AU) | 2019-06-27 | — | — | US | disclosed |
| US-10308653-B2 | Diazepane derivatives and uses thereof | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2019-06-04 | — | — | US | disclosed |
| US-RE47415-E1 | Pyrimidinecarboxamides as CXCR2 modulators | SYNTRIX BIOSYSTEMS, INC. (US) | 2019-06-04 | — | — | US | disclosed |
| US-7575386-B2 | Color-memorizing photochromic writing instrument, color-memorizing photochromic writing instrument set using the same and method for alternately expressing color-memorizing photochromic function of writing image | THE PILOT INK CO., LTD. (JP) | 2009-08-18 | — | — | US | disclosed |
| US-7575386-B2 | Color-memorizing photochromic writing instrument, color-memorizing photochromic writing instrument set using the same and method for alternately expressing color-memorizing photochromic function of writing image | THE PILOT INK CO., LTD. (JP) | 2009-08-18 | — | — | US | disclosed |
| US-7572784-B2 | Compounds and methods for inhibiting mitotic progression | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2009-08-11 | — | — | US | disclosed |
| US-7560467-B2 | Indazolo-tetrahydropyrimidine-carboxamide derivative kinase inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 2009-07-14 | — | — | US | disclosed |
| US-7560467-B2 | Indazolo-tetrahydropyrimidine-carboxamide derivative kinase inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 2009-07-14 | — | — | US | disclosed |
| US-20090170845-A1 | USE OF IMIDAZO[2,1-b]-1,3,4-THIADIAZOLE-2-SULFONAMIDE COMPOUNDS TO TREAT NEUROPATHIC PAIN | AEGERA THERAPEUTICS INC. (CA) | 2009-07-02 | — | — | US | disclosed |
| US-20090170845-A1 | USE OF IMIDAZO[2,1-b]-1,3,4-THIADIAZOLE-2-SULFONAMIDE COMPOUNDS TO TREAT NEUROPATHIC PAIN | AEGERA THERAPEUTICS INC. (CA) | 2009-07-02 | — | — | US | disclosed |
| US-20090156578-A1 | 3-Heterocyclylacrylamide Compounds as Fab I Inhibitors and Antibacterial Agents | DEBIOPHARM INTERNATIONAL SA (CH) | 2009-06-18 | — | — | US | disclosed |
| US-20080045501-A1 | Pyridobenzazepine compounds and methods for inhibiting mitotic progression | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2008-02-21 | — | — | US | disclosed |
| US-20070099944-A1 | Chemical compounds | SMITHKLINE BEECHAM CORPORATION | 2007-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156578-A1 | 3-Heterocyclylacrylamide Compounds as Fab I Inhibitors and Antibacterial Agents | GAA, TFPI, DBI | GPR3 4277/4885ALDH1A1 2669/4885PRNP 3301/4885 |
| US-20090170845-A1 | USE OF IMIDAZO[2,1-b]-1,3,4-THIADIAZOLE-2-SULFONAMIDE COMPOUNDS TO TREAT NEUROPATHIC PAIN | SCN1B, SCN3A, SCN1A | GPR3 380/4885ALDH1A1 658/4885PRNP 2527/4885 |
| US-10308653-B2 | Diazepane derivatives and uses thereof | BRDT, BRD4, BAZ2A | GPR3 1542/4885ALDH1A1 3052/4885PRNP 2206/4885 |
| US-10702527-B2 | Combination therapy of transcription inhibitors and kinase inhibitors | CHUK, BCOR, MYC | GPR3 4280/4885ALDH1A1 3413/4885PRNP 2933/4885 |
| US-20080045501-A1 | Pyridobenzazepine compounds and methods for inhibiting mitotic progression | AURKB, AURKC, AURKA | GPR3 2423/4885ALDH1A1 3480/4885PRNP 4030/4885 |
| US-20210163471-A1 | PROGRANULIN MODULATORS AND METHODS OF USING THE SAME | GRN, PRNP, PSEN1 | GPR3 3197/4885ALDH1A1 4834/4885PRNP 2/4885 |
| US-20070099944-A1 | Chemical compounds | ROCK1, ROCK2, CIT | GPR3 2133/4885ALDH1A1 1692/4885PRNP 3369/4885 |
| US-20190192532-A1 | COMBINATION THERAPY OF BROMODOMAIN INHIBITORS AND CHECKPOINT BLOCKADE | BRD4, BRD3, BRPF3 | GPR3 2851/4885ALDH1A1 3317/4885PRNP 2998/4885 |
| US-20230303581-A1 | ORALLY BIOAVAILABLE, BRAIN-PENETRANT COMPOUND WITH SELECTIVITY FOR THE CANNABINOID TYPE 2 RECEPTOR WITH POTENTIAL USE TOWARDS VISCERAL PAIN MANAGEMENT AND NEURODEGENERATIVE DISORDERS | CNR2, CNR1, OPRL1 | GPR3 47/4885ALDH1A1 3481/4885PRNP 964/4885 |
| US-11236082-B2 | EZH2 inhibitors and uses thereof | EZH2, EZH1, BMI1 | GPR3 4601/4885ALDH1A1 1655/4885PRNP 3043/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.